CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in Trial
- CAR T-cell therapy has driven disease activity down in six patients with severe, treatment-refractory rheumatoid arthritis, with three participants achieving medication-free remission in a world-first clinical trial conducted...
- The first phase of the trial, designated COMPARE, enrolled six patients consisting of three women and three men aged 31 to 69.
- Gerhard Krönke, who leads the joint Clinical Rheumatology research group at Charité and the German Rheumatology Research Center, noted that disease activity decreased markedly across all six individuals.
CAR T-cell therapy has driven disease activity down in six patients with severe, treatment-refractory rheumatoid arthritis, with three participants achieving medication-free remission in a world-first clinical trial conducted by researchers at Charité – Universitätsmedizin Berlin. Findings published in Nature Medicine show the personalized immunotherapy originally developed for cancer successfully targeted harmful immune cells and cleared out abnormal B-cell memory deep within patient tissues.
Six Severe Rheumatoid Arthritis Patients Find Relief in World-First Trial
Inside the COMPARE Trial Design and Patient Outcomes
The first phase of the trial, designated COMPARE, enrolled six patients consisting of three women and three men aged 31 to 69. Over the preceding decade, these participants had tried as many as eight targeted or biologic therapies without achieving adequate relief.
Prof. Gerhard Krönke, who leads the joint Clinical Rheumatology research group at Charité and the German Rheumatology Research Center, noted that disease activity decreased markedly across all six individuals. Three patients maintained sustained remission without any rheumatoid arthritis medication during a follow-up period of up to one year.
Disease activity fell substantially in every participant during the observation period. Researchers observed that the treatment successfully reached and eliminated disease-promoting B cells located in the bone marrow, lymph nodes, and joint tissue. Furthermore, levels of autoantibodies associated with the chronic autoimmune condition dropped sharply over the 12-month monitoring window.
Targeting Persistent Immune Memory in the Body
Rheumatoid arthritis is a chronic autoimmune condition where the immune system mistakenly attacks joints, causing repeated inflammation and eventual tissue damage. While existing anti-inflammatory and immunosuppressive drugs can control symptoms, they rarely cure the condition, leaving some patients with severe treatment-refractory disease marked by chronic pain and limited mobility.
Prof. David Simon, who designed the trial alongside Prof. Gerhard Krönke at Charité’s Department of Rheumatology and Clinical Immunology, explained that memory B cells can survive in lymph nodes, bone marrow, or joint tissue to continually produce harmful antibodies that reignite inflammation.
Adapting Cancer Immunotherapy to Reset the Autoimmune System
To address these persistent cells, doctors adapted CAR T-cell therapy—a personalized treatment where a patient’s own T cells are collected and genetically modified in the laboratory. Scientists equip the T cells with a chimeric antigen receptor designed to bind specifically to CD19, a surface molecule functioning as a name tag on both cancerous B cells and disease-driving B cells.
Patients receive a short course of preparatory chemotherapy to lower certain immune cells, creating space for the engineered cells to multiply before receiving them in a single infusion. When the B-cell system eventually recovered in trial participants, researchers discovered it was composed mostly of naive B cells untouched by the disease, while autoreactive B cells were no longer detectable.